Deep Dive Into Alnylam Pharmaceuticals Stock: Analyst Perspectives (6 Ratings)
Deep Dive Into Alnylam Pharmaceuticals Stock: Analyst Perspectives (6 Ratings)
深入研究阿里拉姆制药股票：分析师观点（6个评级）
A clear picture of Alnylam Pharmaceuticals...6 analysts have shared their evaluations of Alnylam Pharmaceuticals (NASDAQ:AGIO) during the recent three months, expressing a mix of bullish and bearish perspectives.
在最近三个月内有6位分析师分享了对阿里拉姆制药（纳斯达克:AGIO）的评价，表达了看好和看淡观点的混合。
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
在下表中，您将找到他们最近的评级摘要，揭示了过去30天内情绪的变化，并将它们与前几个月进行比较。
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $53.5, with a high estimate of $56.00 and a low estimate of $51.00. This current average represents a 3.17% decrease from the previous average price target of $55.25.
分析师对12个月价格目标的评估提供了额外的见解，展示了53.5美元的平均目标，最高估值为56.00美元，最低估值为51.00美元。当前的平均值较上一个55.25美元的平均价格目标下降了3.17%。
Decoding Analyst Ratings: A Detailed Look
Decoding Analyst Ratings: A Detailed Look
A clear picture of Alnylam Pharmaceuticals...
通过对最近分...
登录免费看全文
登录/注册
资讯热榜
更新时间